The last drug, ziritaxestat, is in phase 3 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) but has been reported to act as an autotaxin inhibitor for cancer treatment when combined in different ways with other small compounds [74]. Here, ENPP2 is linked to idiopathic pulmonary fibrosis.